BUDGET IMPACT EVALUATION OF A PNEUMOCOCCAL CONJUGATED VACCINE (PCV) 13 VALENT VACCINATION WITH FREE CAMPAIGN PROGRAM FOR CORPORATIONS VESUS NO VACCINATION FOR OLDER ADULTS

被引：0

作者：

Fujii, R. K. ^{[1
]}

Presa, J. ^{[1
]}

Roberts, C. S. ^{[2
]}

Gea, Y. ^{[1
]}

Manfrin, D. F. ^{[1
]}

Mould, J. ^{[2
]}

机构：

[1] Pfizer Inc, Sao Paulo, Brazil

[2] Pfizer, New York, NY USA

来源：

VALUE IN HEALTH | 2013年 / 16卷 / 03期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A84 / A84

页数：1

共 50 条

[1] BUDGET IMPACT EVALUATION OF A VACCINATION WITH CAMPAIGN PROGRAM FOR CORPORATIONS USING PNEUMOCOCCAL CONJUGATED VACCINE (PCV) 13 VALENT VERSUS PNEUMOCOCCAL POLISACCHARIDE VACCINE (PPV) 23 WITH PAID CAMPAIGN FOR OLDER ADULTS
Fujii, R. K.
Presa, J.
Roberts, C. S.
Gea, Y.
Manfrin, D. F.
Mould, J.
VALUE IN HEALTH, 2013, 16 (03) : A84 - A85
[2] COST MINIMIZATION COMPARISON OF A VACCINATION WITH CAMPAIGN PROGRAM FOR CORPORATIONS USING PCV13 VESUS FREE PCV10 WITH PAID CAMPAIGN
Fujii, R. K.
Mould, J.
Roberts, C. S.
Presa, J.
Jardim, E.
VALUE IN HEALTH, 2012, 15 (07) : A397 - A397
[3] ECONOMIC IMPACT IN DOMINICAN REPUBLIC SENASA OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) VERSUS NO VACCINATION IN OLDER ADULTS
Del Villar-Tapia, Y.
Brito-Tayson, G.
Lizardo, J.
VALUE IN HEALTH, 2020, 23 : S173 - S173
[4] PNEUMOCOCCAL VACCINATION WITH 13-VALENT POLYSACCHARIDE CONJUGATE VACCINE FOR OLDER ADULTS WITH CHRONIC CONDITIONS: BUDGET IMPACT ANALYSIS IN COLOMBIA
LaRotta, J.
Sanchez, Reyes J. M.
Gamboa, Castano N.
VALUE IN HEALTH, 2022, 25 (01) : S107 - S107
[5] FINANCIAL ANALYSIS OF A VACCINATION CAMPAIGN USING 13 VALENT PNEUMOCOCAL CONJUGATED VACCINE (PCV13) WITH EMPLOYERS
Ferreira, C. N.
Manfrin, D. F.
Rufino, C. S.
VALUE IN HEALTH, 2014, 17 (03) : A270 - A270
[6] A BUDGET IMPACT (BI) ANALYSIS OF VACCINATING THE ELDERLY AND AT-RISK ADULTS WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO NO VACCINATION (NOVAC) OR 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) IN THE UK
Jiang, Y.
Gauthier, A.
Keeping, S. T.
Carroll, S. M.
VALUE IN HEALTH, 2012, 15 (07) : A388 - A388
[7] Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older
Jackson, Lisa A.
Gurtman, Alejandra
van Cleeff, Martin
Frenck, Robert W.
Treanor, John
Jansen, Kathrin U.
Scott, Daniel A.
Emini, Emilio A.
Gruber, William C.
Schmoele-Thoma, Beate
VACCINE, 2013, 31 (35) : 3594 - 3602
[8] PUBLIC HEALTH AND ECONOMIC IMPACT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) IN PUBLIC AND PRIVATE SYSTEM VERSUS PPSV23 AND NO VACCINATION IN OLDER ADULTS
Ferreira, C. N.
Santana, C. F.
Rufino, C.
VALUE IN HEALTH, 2015, 18 (07) : A839 - A839
[9] Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
Gouveia, Miguel
Jesus, Goncalo
Ines, Monica
Costa, Joao
Borges, Margarida
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (04) : 850 - 858
[10] A Dynamic Model to Estimate the Budget Impact of a Pneumococcal Vaccination Program in a 65 Year-old immunocompetent Spanish Cohort with 13 Valent Pneumococcal Conjugate Vaccine
Lorente Antonanzas, Reyes
Varona Malumbres, Juan Luis
Antonanzas Villar, Fernando
Rejas Gutierrez, Javier
REVISTA ESPANOLA DE SALUD PUBLICA, 2016, 90

← 1 2 3 4 5 →